Wave posts results for terminated WVE-004 OLE study in C9orf72 ALS/FTD

Wave Life Sciences USA posted results for its open-label extension study of WVE-004 in C9orf72-associated ALS and FTD, a trial the company had already terminated.

• The Phase 1/2 extension study (NCT05683860) enrolled patients who had completed the earlier Phase 1b/2a WVE-004-001 study and gave them 10 mg of WVE-004 by intrathecal injection every 12 weeks for a planned 96 weeks.¹ The trial was marked terminated because Wave decided to stop development of WVE-004 based on the available data findings.¹ Actual enrollment reached 8 participants.¹ Primary completion and study completion were both dated 2023-06-27, and results were first posted on 2026-09-09.¹ The main safety measure tracked adverse events, serious adverse events, and withdrawals due to adverse events from Day 1 through the point of early termination at Week 24.